Niagen Bioscience Inc reports results for the quarter ended September 30 - Earnings Summary

• Niagen Bioscience Inc reported quarterly adjusted earnings of 1 cent​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of 5 cents. The mean expectation of six analysts for the quarter was for breakeven results per share. Wall Street expected results to range from -3 cents to 2 cents per share.

• Revenue fell 20% to $27.19 million from a year ago; analysts expected $30.69 million.

• Niagen Bioscience Inc's reported EPS for the quarter was 1 cent​.

• The company reported quarterly net income of $1.17 million.

• Niagen Bioscience Inc shares had fallen by 19.2% this quarter and lost 62.9% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 91.6% in the last three months.​

• In the last 30 days, three analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Niagen Bioscience Inc is $10.00, about 76.4% above its last closing price of $2.36

This summary was machine generated from LSEG data November 4 at 10:41 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)